🔎 Trials Near Me

Utama › Neoplasma Mieloproliferatif › Kansas

Kajian klinikal Neoplasma Mieloproliferatif di Kansas

6 kajian untuk Neoplasma Mieloproliferatif sedang mencari peserta di lokasi di Kansas.

Bandar di Kansas

Teks kajian rasmi (Bahasa Inggeris)

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

  • University of Kansas Clinical Research Center, Fairway
  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Hospital-Indian Creek Campus, Overland Park
  • dan 1 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06661915

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • University of Kansas Clinical Research Center, Fairway
  • HaysMed, Hays
  • University of Kansas Cancer Center, Kansas City
  • dan 7 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05564390

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • University of Kansas Clinical Research Center, Fairway
  • University of Kansas Cancer Center, Kansas City
  • University of Kansas Hospital-Indian Creek Campus, Overland Park
  • dan 1 lagi
Mengambil pesertaFasa 2
Umur 18 hingga 59 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT05554406

Project: Every Child for Younger Patients With Cancer

  • Wesley Medical Center, Wichita
Mengambil pesertaKajian pemerhatian
Sehingga umur 25 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT02402244

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  • The University of Kansas Cancer Center, Westwood
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Apr 2026 · NCT06034002

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.